Rivaroxaban or aspirin for extended treatment of venous thromboembolism
JI Weitz, AWA Lensing, MH Prins… - … England Journal of …, 2017 - Mass Medical Soc
Background Although many patients with venous thromboembolism require extended
treatment, it is uncertain whether it is better to use full-or lower-intensity anticoagulation …
treatment, it is uncertain whether it is better to use full-or lower-intensity anticoagulation …
Oral rivaroxaban for symptomatic venous thromboembolism
Einstein Investigators - New England Journal of Medicine, 2010 - Mass Medical Soc
Background Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose
regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without …
regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without …
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized …
MH Prins, AWA Lensing, R Bauersachs, B Van Bellen… - Thrombosis journal, 2013 - Springer
Background Standard treatment for venous thromboembolism (VTE) consists of a heparin
combined with vitamin K antagonists. Direct oral anticoagulants have been investigated for …
combined with vitamin K antagonists. Direct oral anticoagulants have been investigated for …
Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism–the J-EINSTEIN DVT and PE program
N Yamada, A Hirayama, H Maeda, S Sakagami… - Thrombosis journal, 2015 - Springer
Abstract Background The global EINSTEIN DVT and PE studies compared rivaroxaban (15
mg twice daily for 3 weeks followed by 20 mg once daily) with enoxaparin/vitamin K …
mg twice daily for 3 weeks followed by 20 mg once daily) with enoxaparin/vitamin K …
Risk of recurrent venous thromboembolism according to baseline risk factor profiles
MH Prins, AWA Lensing, P Prandoni, PS Wells… - Blood …, 2018 - ashpublications.org
The optimal duration of anticoagulation for venous thromboembolism (VTE) is uncertain. In
this prespecified analysis, we used data from 2 randomized trials, which compared once …
this prespecified analysis, we used data from 2 randomized trials, which compared once …
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
Einstein–PE Investigators - New England journal of medicine, 2012 - Mass Medical Soc
Background A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been
shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein …
shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein …
Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous …
Background Apixaban and rivaroxaban, both direct-acting oral anticoagulants, are being
increasingly used in routine clinical practice because of their fixed dosing and favourable …
increasingly used in routine clinical practice because of their fixed dosing and favourable …
Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism
B van Bellen, L Bamber… - … medical research and …, 2014 - Taylor & Francis
Abstract Objective: The phase III EINSTEIN DVT and EINSTEIN PE trials demonstrated the
potential of oral rivaroxaban for the treatment of deep vein thrombosis (DVT) and pulmonary …
potential of oral rivaroxaban for the treatment of deep vein thrombosis (DVT) and pulmonary …
Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study)
E Romualdi, MP Donadini, W Ageno - Expert review of …, 2011 - Taylor & Francis
Over recent years, research on anticoagulant drugs has been guided by the requirement for
convenient administration and a wide therapeutic window to allow fixed dosing without the …
convenient administration and a wide therapeutic window to allow fixed dosing without the …
Treatment of venous thromboembolism with new anticoagulant agents
C Becattini, G Agnelli - Journal of the American College of Cardiology, 2016 - jacc.org
Venous thromboembolism (VTE) is a common disease associated with high risk for
recurrences, death, and late sequelae, accounting for substantial health care costs …
recurrences, death, and late sequelae, accounting for substantial health care costs …
相关搜索
- rivaroxaban or aspirin extended treatment
- rivaroxaban or aspirin venous thromboembolism
- venous thromboembolism extended treatment
- venous thromboembolism bleeding events
- venous thromboembolism safety of apixaban
- venous thromboembolism cohort analysis
- venous thromboembolism rivaroxaban for prevention
- venous thromboembolism effectiveness and safety